HbA1c News and Research

RSS

Positive interim data from XBiotech monoclonal antibody Phase II study for type 2 diabetes

XBiotech, a privately held biotechnology company, announced positive interim analysis results today from a Phase II study using a True Human monoclonal antibody (MABp1) in patients with type 2 diabetes. Results from this study continue to reinforce the role of IL-1α as a master regulator of chronic inflammation in multiple disease states, and the therapeutic benefits of neutralizing antibodies produced from the XBiotech platform.

29 Oct 2012

Results of diabetes management program to be presented at Canadian Cardiovascular Congress

In Canada alone, almost 2 million people are known to be living with diabetes. And around a million more have the disease but are not aware of that fact, and have not been given the tools they need to control their blood sugar and safeguard their health.

29 Oct 2012

HbA1c equally useful across ethnic groups

Currently recommended clinical cutoff points for diabetes diagnosis using glycated hemoglobin should be interpreted similarly in Whites, Blacks, and Hispanics, show findings from a US study.

26 Oct 2012

HbA1c equally useful across ethnic groups

Currently recommended clinical cutoff points for diabetes diagnosis using glycated hemoglobin should be interpreted similarly in Whites, Blacks, and Hispanics, show findings from a US study.

25 Oct 2012

Legume intake reduces heart disease risk in diabetes patients

Diabetes patients who incorporate legumes as part of a low glycemic index diet improve their glycemic control and reduce their risk for coronary heart disease, a study shows.

25 Oct 2012

Canadian Task Force updates diabetes screening guidelines

The Canadian Task Force on Preventive Health Care has updated its recommendations on screening asymptomatic adults for Type 2 diabetes.

19 Oct 2012

Quality of care drops if doctors dictate

Physicians who predominantly dictate patients’ medical notes have worse quality of care than their peers who use structured electronic health record documentation, show study findings.

19 Oct 2012

One rule for one and one for another with diabetes

A joint consensus statement from the European Association for the Study of Diabetes and the American Diabetes Association encourages a shift in attitude over glycemic management in Type 2 diabetes.

12 Oct 2012

HbA1c converter tool launched by NPS

NPS MedicineWise has launched a new online HbA1c converter tool to help people with diabetes understand changes to the way their HbA1c test results are reported in Australia.

10 Oct 2012

Long-term education for patients may futher improve diabetes outcomes

Although there have been significant advances in the provision of diabetes education since 2000, further improvements are still needed, say researchers.

5 Oct 2012

MannKind completes enrollment in AFREZZA Phase 3 clinical studies for type 1 and 2 diabetes

MannKind Corporation today announced that it has completed recruiting patients for two Phase 3 clinical studies of AFREZZA (insulin human [rDNA origin]), an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind's to-be-marketed next-generation inhaler.

5 Oct 2012

InsuPad device may improve insulin therapy

A novel device is currently under development for aiding insulin analog therapy in diabetes patients, report researchers.

4 Oct 2012

Hormone therapy offsets adverse metabolic effects of menopause

Long-term hormone therapy helps prevent the adverse metabolic effects that occur following menopause, research shows.

4 Oct 2012

Insulin degludec shows promise in diabetes

Self-administration of daily insulin degludag injections is no less effective than self-injecting insulin glargine in patients with diabetes who are new to insulin therapy, say researchers.

4 Oct 2012

One rule for one and one for another with diabetes

A joint consensus statement from the European Association for the Study of Diabetes and the American Diabetes Association encourages a shift in attitude over glycemic management in Type 2 diabetes.

2 Oct 2012

Intarcia announces results from ITCA 650 phase 2 study on type 2 diabetes

Intarcia Therapeutics, Inc. announced that an analysis of the results of a phase 2 clinical study of ITCA 650 (continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes will be presented at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany on Wednesday, October 3, 2012.

29 Sep 2012